GutHeart: Targeting Gut Microbiota to Treat Heart Failure

NCT02637167 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Systolic Heart Failure

Interventions

DRUG: Rifaximin
DRUG: Saccharomyces boulardii

Sponsor

Oslo University Hospital